158 related articles for article (PubMed ID: 16436489)
1. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M
Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
[TBL] [Abstract][Full Text] [Related]
4. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
[TBL] [Abstract][Full Text] [Related]
5. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
6. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
[TBL] [Abstract][Full Text] [Related]
7. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
Baraliakos X; Listing J; Rudwaleit M; Brandt J; Alten R; Burmester G; Gromnica-Ihle E; Haibel H; Schewe S; Schneider M; Sörensen H; Zeidler H; Visvanathan S; Sieper J; Braun J
J Rheumatol; 2007 Mar; 34(3):510-5. PubMed ID: 17299842
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment in ankylosing spondylitis: an observational study.
Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
[TBL] [Abstract][Full Text] [Related]
10. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
[TBL] [Abstract][Full Text] [Related]
11. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis].
Vinagre F; Santos MJ; Silva JC
Acta Reumatol Port; 2007; 32(3):271-3. PubMed ID: 17940497
[TBL] [Abstract][Full Text] [Related]
12. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis.
Chu Miow Lin D; Mulleman D; Azzopardi N; Griffoul-Espitalier I; Valat JP; Paintaud G; Goupille P
Scand J Rheumatol; 2010; 39(1):97-8. PubMed ID: 20132079
[No Abstract] [Full Text] [Related]
13. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup.
Keeling S; Oswald A; Russell AS; Maksymowych WP
J Rheumatol; 2006 Mar; 33(3):558-61. PubMed ID: 16463437
[TBL] [Abstract][Full Text] [Related]
14. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
Baraliakos X; Listing J; Fritz C; Haibel H; Alten R; Burmester GR; Krause A; Schewe S; Schneider M; Sörensen H; Schmidt R; Sieper J; Braun J
Rheumatology (Oxford); 2011 Sep; 50(9):1690-9. PubMed ID: 21672969
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
[TBL] [Abstract][Full Text] [Related]
16. The use of infliximab in academic rheumatology practice: an audit of early clinical experience.
Fitzcharles MA; Clayton D; Ménard HA
J Rheumatol; 2002 Dec; 29(12):2525-30. PubMed ID: 12465146
[TBL] [Abstract][Full Text] [Related]
17. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
20. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X; Listing J; Brandt J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Rudwaleit M; Sieper J; Braun J
Arthritis Res Ther; 2005; 7(3):R439-44. PubMed ID: 15899030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
